Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adecoagro SA (AGRO) vs Smith & Nephew plc (SNN) Price & Performance

Adecoagro SATrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Adecoagro SA vs Smith & Nephew plc — how do they compare? Adecoagro SA trades at $9.14 (market cap $1.36B), while Smith & Nephew plc trades at $29.55 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 9.2× Adecoagro SA's market cap, and Adecoagro SA pays the higher dividend (3.15%). Which is the better fit depends on your goals.

AGROSNN
Market Cap
$1.36B$12.54B
Sector
TechnologyHealth
52-Week High
$15.25$38.70
52-Week Low
$7.13$28.73
Enterprise Value
$3.39B$15.57B
Dividend Yield
3.15%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adecoagro SA

No Aura AI signal available yet.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.

Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.

Returns comparison

Trailing returns across standard periods

About Adecoagro SA

Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.

Read more on AGRO

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN